Journal of Basic Research in Medical Sciences
J Basic Res Med Sci
Volume 12, Issue 3 (5-2025)
jbrms 2025, 12(3): 64-74 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Madani M M, Abednatanzi H, Gholami M, Ghazalian F. The effect of 12 weeks of intermittent resistance training with Algomed supplementation on plasma levels of Fetuin A and Fetuin B in men with obesity. jbrms 2025; 12 (3) :64-74
URL: http://jbrms.medilam.ac.ir/article-1-846-en.html
URL: http://jbrms.medilam.ac.ir/article-1-846-en.html
Department of professional Physical Education and Sports Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran , abednazari@gmail.com
Abstract: (12 Views)
Introduction: Fetuin A and B are hepatokines linked to obesity and metabolic disorders. The present study aimed to investigate the effect of 12 weeks of intermittent resistance training combined with Algomed (Chlorella vulgaris) supplementation on plasma levels of fetuin A and B in obese men.
Materials & Methods: This quasi-experimental study included 44 obese men (BMI > 30), aged 23–32 years, randomly assigned to four groups (n = 11 each): control, resistance training, Algomed supplementation, and resistance training + Algomed. The training protocol was performed three times per week for 12 weeks. The supplement groups received 1800 mg/day of Algomed. Plasma levels of fetuin A and B were measured by ELISA before and after the intervention. Baseline differences were assessed using one-way ANOVA. Within-group changes were analyzed using paired t-tests, and between-group comparisons of post-test values were conducted using ANCOVA with initial values as covariates. Bonferroni post hoc tests were applied where appropriate (p < 0.05).
Results: ANCOVA results showed significant differences in post-test levels of both fetuin A and fetuin B between the groups (p < 0.0001). Post hoc analysis indicated that the training + Algomed group had significantly lower fetuin-A levels compared to the control group. Furthermore, fetuin-B levels were significantly reduced in all intervention groups compared to the control, with the greatest reduction observed in the training + Algomed group compared to all other groups (p < 0.0001).
Conclusion: Twelve weeks of intermittent resistance training combined with Algomed supplementation had a synergistic effect in reducing plasma levels of fetuin A and B in obese men. These findings suggest potential metabolic benefits for this combined intervention strategy.
Materials & Methods: This quasi-experimental study included 44 obese men (BMI > 30), aged 23–32 years, randomly assigned to four groups (n = 11 each): control, resistance training, Algomed supplementation, and resistance training + Algomed. The training protocol was performed three times per week for 12 weeks. The supplement groups received 1800 mg/day of Algomed. Plasma levels of fetuin A and B were measured by ELISA before and after the intervention. Baseline differences were assessed using one-way ANOVA. Within-group changes were analyzed using paired t-tests, and between-group comparisons of post-test values were conducted using ANCOVA with initial values as covariates. Bonferroni post hoc tests were applied where appropriate (p < 0.05).
Results: ANCOVA results showed significant differences in post-test levels of both fetuin A and fetuin B between the groups (p < 0.0001). Post hoc analysis indicated that the training + Algomed group had significantly lower fetuin-A levels compared to the control group. Furthermore, fetuin-B levels were significantly reduced in all intervention groups compared to the control, with the greatest reduction observed in the training + Algomed group compared to all other groups (p < 0.0001).
Conclusion: Twelve weeks of intermittent resistance training combined with Algomed supplementation had a synergistic effect in reducing plasma levels of fetuin A and B in obese men. These findings suggest potential metabolic benefits for this combined intervention strategy.
Type of Study: Research |
Received: 2024/04/13 | Accepted: 2024/07/14 | Published: 2025/05/11
Received: 2024/04/13 | Accepted: 2024/07/14 | Published: 2025/05/11
References
1. Karaderi T, Drong AW, Lindgren CM. Insights into the genetic susceptibility to type 2 diabetes from genome-wide association studies of obesity-related traits. Current diabetes reports. 2015;15(10):83. doi:10.1016/j.metabol.2016.11.017
2. Lee M-J, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2014;1842(3):473-81. doi:10.1016/j.bbadis.2013.05.029
3. De Andrade I, Zemdegs J, De Souza A, Watanabe R, Telles M, Nascimento C, et al. Diet-induced obesity impairs hypothalamic glucose sensing but not glucose hypothalamic extracellular levels, as measured by microdialysis. Nutrition & diabetes. 2015;5(6):e162. doi:10.1038/nutd.2015.12
4. Segula D. Complications of obesity in adults: a short review of the literature. Malawi Med J. 2014;26(1):20-4.
5. Poggiogalle E, Lubrano C, Gnessi L, Mariani S, Di Martino M, Catalano C, et al. The decline in muscle strength and muscle quality in relation to metabolic derangements in adult women with obesity. Clinical Nutrition. 2019. doi:10.1016/j.clnu.2019.01.028
6. Pacifico L, Perla FM, Chiesa C. Sarcopenia and nonalcoholic fatty liver disease: a causal relationship. Hepatobiliary surgery and nutrition. 2019;8(2):144. doi:10.21037/hbsn.2018.11.11
7. Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Tarasow E, Wojtkowska M, Lebensztejn DM. Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children? Advances in medical sciences. 2019;64(2):280-4. doi:10.1016/j.advms.2019.02.005
8. Lebensztejn DM, Flisiak-Jackiewicz M, Białokoz-Kalinowska I, Bobrus-Chociej A, Kowalska I. Hepatokines and non-alcoholic fatty liver disease. Acta Biochimica Polonica. 2016;63(3):459-67.doi:10.18388/abp.2015_1252
9. Meex RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell metabolism. 2015;22(6):1078-89.doi:10.1016/j.cmet.2015.09.023
10. Yoo HJ, Choi KM. Hepatokines as a link between obesity and cardiovascular diseases. Diabetes Metab J; dmj. 2015;39(1):10-5. doi:10.4093/dmj.2015.39.1.10
11. Meex RC, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nature Reviews Endocrinology. 2017;13(9):509-20.
12. Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the US. Diabetes. 2013;62(1):49-55. doi:10.2337/db12-0372
13. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):352-9.
14. Laughlin GA, Cummins KM, Wassel CL, Daniels LB, Ix JH. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am CollCardiol.2012;59(19):1688-96. doi:10.1016/j.jacc.2012.01.038
15. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113(14):1760-7. doi:10.1161/CIRCULATIONAHA.105.58872
16. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur. J. Endocrinol. 2012;166(3):503. doi:10.1530/EJE-11-0864
17. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost H-G, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555-62. doi:10.1161/CIRCULATIONAHA.108.814418
18. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, et al. α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes care. 2006;29(4):853-7. doi:10.2337/diacare.29.04.06.dc05-1938
19. Brzycki M. Strength testing—predicting a one-rep max from reps-to-fatigue. J.Phys.Edus.Recreat.Dance. 1993;64(1):88-90. doi:10.1080/07303084.1993.10606684
20. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, et al. NF-κB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem. J. 2010;429(3):451-62. doi: 10.1042/BJ20100330
21. Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, Kumon Y, et al. High glucose induces transactivation of the α2-HS glycoprotein gene through the ERK1/2 signaling pathway.J Atheroscler Thromb. 2009:0908100070-.doi:10.5551/jat.No950
22. Denecke B. Gräber s, schäfer C, Heiss A, Wöltje M and Jahnendechent W: Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-a. Biochem J. 2003;376:135-45. doi:10.1042/bj20030676
23. Kralisch S, Hoffmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, et al. Regulation of the novel adipokines/hepatokines fetuin A and fetuin B in gestational diabetes mellitus. Metabolism. 2017;68:88-94. doi:10.1016/j.metabol.2016.11.017
24. Pan X, Kaminga AC, Chen J, Luo M, Luo J. Fetuin-A and Fetuin-B in non-alcoholic fatty liver disease: a meta-analysis and meta-regression. Int. J. Environ. Res. Public Health. 2020;17(8):2735. doi:10.3390/ijerph17082735
25. Ennequin G, Sirvent P, Whitham M. Role of exercise-induced hepatokines in metabolic disorders. Am J Physiol Endocrinol Metab. 2019;317(1):E11-E24. doi:10.1152/ajpendo.00433.2018
26. Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B, et al. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescriptionan advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, american heart association. Circulation. 2000;101(7):828-33. doi:10.1161/01.CIR.101.7.828
27. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA. American College of Sports Medicine position stand. Exercise and hypertension. Medicine and Science in Sports and Exercise. 2004;36(3):20.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |